Quviviq is granted EU approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder.
Idorsia Ltd announced the European Commission (EC) has granted marketing authorization for Quviviq (daridorexant) for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.
Chronic insomnia disorder is one of the most prevalent sleep disorders in Europe, affecting between 6%-12% of the adult population, and impacting both physical and mental health.
With this approval, Quviviq becomes the first dual orexin receptor antagonist (DORA) in the European Union (EU) for the treatment of insomnia. Rather than inducing sleep through broad inhibition of brain activity, Quviviq blocks only the activation of orexin receptors. Consequently, Quviviq decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages.
Related news and insights
Roche announced that the European Commission (EC) has granted approval of Polivy (polatuzumab vedotin) in combination with MabThera(rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
NICE- National Institute for Health and Care Excellence (UK) Guidance:1.1 Romosozumab (Evenity)from UCB + Amgen, is recommended as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if: they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) and the company provides romosozumab according to the commercial arrangement.